RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
--
--(--)
RLMD fundamentals
During Q4 2025, Relmada Therapeutics (RLMD) reported revenue of --, a YoY change of 0.00%. Net income was -19.87M, a YoY change of -6.49%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2018 | Q2,2018 | Q3,2018 | Q4,2018 | Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2017 | Oct 1, 2017 | Jan 1, 2018 | Apr 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2017 | Dec 31, 2017 | Mar 31, 2018 | Jun 30, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 980.86K -- | 1.46M -- | 2.55M -- | 1.93M -- | 2.41M +145.83% | 3.48M +138.85% | 2.70M +5.96% | 4.14M +114.27% | 3.71M +53.76% | 12.76M +266.69% | 17.18M +535.96% | 20.92M +405.92% | 22.41M +504.34% | 26.46M +107.43% | 42.65M +148.22% | 34.18M +63.37% | 38.30M +70.93% | 45.51M +71.99% | 38.74M -9.18% | 38.70M +13.22% | 28.15M -26.49% | 26.03M -42.81% | 22.69M -41.42% | 26.83M -30.68% | 22.99M -18.35% | 18.82M -27.69% | 23.01M +1.39% | 19.08M -28.90% | 18.22M -20.75% | 10.22M -45.69% | 10.33M -55.12% | 20.33M +6.59% | 59.10M -- |
Selling, General and Administrative Expenses | 815.11K -- | 1.31M -- | 883.01K -- | 970.87K -- | 989.75K +21.43% | 2.22M +70.12% | 1.43M +61.50% | 1.07M +9.78% | 1.82M +83.89% | 7.43M +234.60% | 5.95M +316.98% | 6.02M +464.80% | 8.38M +360.59% | 9.13M +22.83% | 8.66M +45.63% | 8.91M +48.00% | 13.28M +58.47% | 14.60M +59.90% | 8.21M -5.22% | 11.83M +32.83% | 12.29M -7.47% | 12.29M -15.84% | 12.24M +49.10% | 12.08M +2.06% | 9.68M -21.23% | 8.10M -34.09% | 11.86M -3.10% | 8.08M -33.13% | 6.27M -35.27% | 7.40M -8.59% | 6.29M -46.95% | 12.26M +51.82% | 32.22M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 24.87M -- | -- -- | -- -- | -- -- | 35.08M +41.08% | -- -- | -- -- | -- -- | 47.93M +36.61% | -- -- | -- -- | 12.24M -- | 12.08M -74.80% | 9.68M -- | 8.10M -- | 11.86M -3.10% | 8.08M -33.13% | 6.27M -35.27% | 7.40M -8.59% | 6.29M -46.95% | 12.26M +51.82% | 32.22M -- |
Research and Development Expenses | 165.75K -- | 150.72K -- | 1.67M -- | 959.25K -- | 1.42M +757.61% | 1.26M +734.27% | 1.28M -23.45% | 3.07M +220.03% | 1.89M +32.77% | 5.32M +323.40% | 11.24M +780.69% | 14.90M +385.48% | 14.02M +642.95% | 17.33M +225.54% | 33.99M +202.51% | 25.27M +69.58% | 25.01M +78.38% | 30.91M +78.36% | 30.53M -10.19% | 26.87M +6.31% | 15.86M -36.59% | 13.74M -55.55% | 10.45M -65.76% | 14.75M -45.10% | 13.31M -16.11% | 10.72M -21.97% | 11.15M +6.65% | 11.00M -25.43% | 11.95M -10.18% | 2.82M -73.70% | 4.04M -63.80% | 8.07M -26.61% | 26.88M -- |
Operating Income | -980.86K -- | -1.46M -- | -2.55M -- | -1.93M -- | -2.41M -145.83% | -3.48M -138.85% | -2.70M -5.96% | -4.14M -114.27% | -3.71M -53.76% | -12.76M -266.69% | -17.18M -535.96% | -20.92M -405.92% | -22.41M -504.34% | -26.46M -107.43% | -42.65M -148.22% | -34.18M -63.37% | -38.30M -70.93% | -45.51M -71.99% | -38.74M +9.18% | -38.70M -13.22% | -28.15M +26.49% | -26.03M +42.81% | -22.69M +41.42% | -26.83M +30.68% | -22.99M +18.35% | -18.82M +27.69% | -23.01M -1.39% | -19.08M +28.90% | -18.22M +20.75% | -10.22M +45.69% | -10.33M +55.12% | -20.33M -6.59% | -59.10M -- |
Non-Operating Income (Loss) | -830 -- | 29.23K -- | -651.97K -- | -1.42M -- | -968.86K -116630.48% | -3.65M -12586.15% | 15.94K +102.44% | 13.11K +100.92% | 37.92K +103.91% | 1.64M +144.89% | 281.07K +1663.44% | 161.32K +1130.52% | 190.02K +401.17% | -90.06K -105.50% | 47.44K -83.12% | -195.72K -221.32% | -1.45M -862.21% | 5.58M +6292.38% | -681.55K -1536.53% | 758.05K +487.32% | 1.83M +226.49% | 723.77K -87.02% | 690.58K +201.33% | 1.66M +119.53% | 1.16M -36.70% | 1.05M +45.16% | 1.28M +85.77% | 418.42K -74.86% | 658.97K -43.18% | 354.86K -66.22% | 235.85K -81.62% | 465.35K +11.22% | 1.72M -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -16.95K -- | -- -- | -- -- | -- -- | -1.25M -7260.99% | -- -- | -- -- | -- -- | -4.81M -285.27% | -- -- | -- -- | -630.86K -- | 404.94K +108.43% | 103.85K -- | 87.65K -- | 426.39K +167.59% | -242.96K -160.00% | 218.68K +110.58% | 33.41K -61.89% | -11.16K -102.62% | -320.13K -31.76% | -79.21K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 6.74K -- | -- -- | -- -- | -- -- | 398.25K +5813.21% | -- -- |
Other Non-Operating Income (Loss) | -3.35K -- | 341.11K -- | -254.86K -- | -789.44K -- | -318.54K -9403.01% | -3.51M -1129.17% | -- -- | 0 +100.00% | -- -- | 1.64M +146.68% | 281.07K -- | -1.22M -- | 190.02K -- | -90.06K -105.50% | 47.44K -83.12% | -147.40K +87.93% | -1.45M -862.21% | 5.58M +6292.38% | -681.55K -1536.53% | 2.90M +2070.40% | 1.83M +226.49% | 723.77K -87.02% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -2.52K -- | 311.87K -- | 397.11K -- | 630.37K -- | 650.32K +25885.96% | 139.76K -55.18% | -15.94K -104.01% | -13.11K -102.08% | -37.92K -105.83% | -- -- | -- -- | -1.40M -10572.96% | -- -- | -- -- | -- -- | -1.20M +14.30% | -- -- | -- -- | -- -- | -2.66M -121.79% | -- -- | -- -- | -1.32M -- | -1.26M +52.65% | -1.06M -- | -963.01K -- | -856.48K +35.19% | -654.64K +48.01% | -440.29K +58.30% | -321.46K +66.62% | -247.01K +71.16% | -387.23K +40.85% | -1.40M -- |
Pretax Income From Continuing Operations | -981.69K -- | -1.43M -- | -3.20M -- | -3.35M -- | -3.38M -244.32% | -7.13M -399.48% | -2.69M +16.11% | -4.12M -23.06% | -3.67M -8.56% | -11.12M -55.95% | -16.90M -529.27% | -20.76M -403.62% | -22.22M -505.40% | -26.55M -138.81% | -42.61M -152.07% | -34.38M -65.58% | -39.75M -78.91% | -39.93M -50.40% | -39.42M +7.48% | -37.94M -10.37% | -26.32M +33.78% | -25.30M +36.64% | -22.00M +44.18% | -25.17M +33.68% | -21.83M +17.07% | -17.77M +29.78% | -21.73M +1.25% | -18.66M +25.86% | -17.56M +19.56% | -9.87M +44.47% | -10.09M +53.55% | -19.87M -6.49% | -57.39M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -981.69K -- | -1.43M -- | -3.20M -- | -3.35M -- | -3.38M -244.32% | -7.13M -399.48% | -2.69M +16.11% | -4.12M -23.06% | -3.67M -8.56% | -11.12M -55.95% | -16.90M -529.27% | -20.76M -403.62% | -22.22M -505.40% | -26.55M -138.81% | -42.61M -152.07% | -34.38M -65.58% | -39.75M -78.91% | -39.93M -50.40% | -39.42M +7.48% | -37.94M -10.37% | -26.32M +33.78% | -25.30M +36.64% | -22.00M +44.18% | -25.17M +33.68% | -21.83M +17.07% | -17.77M +29.78% | -21.73M +1.25% | -18.66M +25.86% | -17.56M +19.56% | -9.87M +44.47% | -10.09M +53.55% | -19.87M -6.49% | -57.39M -- |
Net Income Attributable to Owners of the Company | -981.69K -- | -1.43M -- | -3.20M -- | -3.35M -- | -3.38M -244.32% | -7.13M -399.48% | -2.69M +16.11% | -4.12M -23.06% | -3.67M -8.56% | -11.12M -55.95% | -16.90M -529.27% | -20.76M -403.62% | -22.22M -505.40% | -26.55M -138.81% | -42.61M -152.07% | -34.38M -65.58% | -39.75M -78.91% | -39.93M -50.40% | -39.42M +7.48% | -37.94M -10.37% | -26.32M +33.78% | -25.30M +36.64% | -22.00M +44.18% | -25.17M +33.68% | -21.83M +17.07% | -17.77M +29.78% | -21.73M +1.25% | -18.66M +25.86% | -17.56M +19.56% | -9.87M +44.47% | -10.09M +53.55% | -19.87M -6.49% | -57.39M -- |
Net Income Attributable to Common Stockholders | -981.69K -- | -1.43M -- | -3.20M -- | -3.35M -- | -3.38M -244.32% | -7.13M -399.48% | -2.69M +16.11% | -4.12M -23.06% | -3.67M -8.56% | -11.12M -55.95% | -16.90M -529.27% | -20.76M -403.62% | -22.22M -505.40% | -26.55M -138.81% | -42.61M -152.07% | -34.38M -65.58% | -39.75M -78.91% | -39.93M -50.40% | -39.42M +7.48% | -37.94M -10.37% | -26.32M +33.78% | -25.30M +36.64% | -22.00M +44.18% | -25.17M +33.68% | -21.83M +17.07% | -17.77M +29.78% | -21.73M +1.25% | -18.66M +25.86% | -17.56M +19.56% | -9.87M +44.47% | -10.09M +53.55% | -19.87M -6.49% | -57.39M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Basic EPS | -0.08 -- | -0.11 -- | -0.26 -- | -0.27 -- | -1.08 -1250.00% | -0.28 -154.55% | -0.09 +65.38% | -0.33 -22.22% | -0.38 +64.81% | -0.73 -160.71% | -1.05 -1066.67% | -1.27 -284.85% | -1.34 -252.63% | -1.56 -113.70% | -2.44 -132.38% | -1.24 +2.36% | -1.4 -4.48% | -1.33 +14.74% | -1.31 +46.31% | -1.26 -1.61% | -0.87 +37.86% | -0.84 +36.84% | -0.73 +44.27% | -0.84 +33.33% | -0.72 +17.24% | -0.59 +29.76% | -0.72 +1.37% | -0.62 +26.19% | -0.58 +19.44% | -0.3 +49.15% | -0.3 +58.33% | -0.27 +56.45% | -1.45 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.73 -- | -- -- | -0.72 -- | -0.59 -- | -0.72 +1.37% | -- -- | -0.58 +19.44% | -0.3 +49.15% | -0.3 +58.33% | -- -- | -- -- |
Diluted EPS | -0.08 -- | -0.11 -- | -0.26 -- | -- -- | -1.08 -1250.00% | -0.28 -154.55% | -0.09 +65.38% | -- -- | -0.38 +64.81% | -0.73 -160.71% | -1.05 -1066.67% | -- -- | -1.34 -252.63% | -1.56 -113.70% | -2.44 -132.38% | -- -- | -1.4 -4.48% | -1.33 +14.74% | -1.31 +46.31% | -- -- | -0.87 +37.86% | -0.84 +36.84% | -0.73 +44.27% | -- -- | -0.72 +17.24% | -0.59 +29.76% | -0.72 +1.37% | -- -- | -0.58 +19.44% | -0.3 +49.15% | -0.3 +58.33% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.73 -- | -- -- | -0.72 -- | -0.59 -- | -0.72 +1.37% | -- -- | -0.58 +19.44% | -0.3 +49.15% | -0.3 +58.33% | -- -- | -- -- |
You can ask Aime
What is Relmada Therapeutics's gross profit margin?What is the market's earnings forecast for Relmada Therapeutics next quarter?Did Relmada Therapeutics beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Relmada Therapeutics year over year?What were the key takeaways from Relmada Therapeutics's earnings call?What factors drove the changes in Relmada Therapeutics's revenue and profit?What guidance did Relmada Therapeutics's management provide for the next earnings period?What were the key takeaways from Relmada Therapeutics’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
